LIN vs RAPP · P/E 34, rev $33.99B vs $532.9M cap
Linde plc Ordinary Shares (LIN) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
Linde plc Ordinary Shares (LIN) is a specialty chemicals company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported LIN revenue for 2025-12-31 was $33.99B. Net income was $6.90B. Revenue was up 3.0% from 2024-12-31 to 2025-12-31. LIN currently screens at market cap $223.87B and trailing P/E 34.5.
RAPP does not have a complete income-statement cache yet.
LIN currently screens at market cap $223.87B and trailing P/E 34.5. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the LIN and RAPP stock pages for the full models.
Not investment advice.